Ritchlin CT, et al. Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study. ACR 2018, abstract L17.
ACR 2018
okt 2018
nov 2022 | Psoriasis
nov 2020
okt 2020
aug 2020 | RA, SLE